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This study was performed to assess the potential toxicity of nanocalcium in terms of 
physico-chemical characteristics. After the blind test of seven samples of calcium 
provided from Korea Food and Drug Administration using energy-filtering 
transmission electron microscopy (EF-TEM), componential analysis using X-ray 
diffractometry (XRD), and energy dispersive spectrometry, two samples of nano and 
micro sized calcium were selected for further study. The characteristics of nano and 
microcalcium were evaluated by EF-TEM, field-emission scanning electron 
microscopy, XRD, dynamic light scattering, and electron spin resonance. Both samples 
were agglomerated and did not produce any measurable reactive oxygen species. The 
specific surface area of nano- and microcalcium measured by the N2 Brunauere 
Emmette Teller (BET) method was 12.90 ± 0.27 m2/g, and 1.12 ± 0.19 m2/g, 
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respectively. Inductively coupled plasma optical emission spectrometry (ICP-OES) 
analysis revealed the release of 2–3 times more calcium ion from nanocalcium 
compared to microcalcium at pH 5 and 7. Genotoxicity and single-dose and repeated-
dose 14-days oral toxicity testing in Sprague-Dawley rats were performed to evaluate 
the safety of nanocalcium. The results of BET and ICP-OES analysis showed that 
nanocalcium has a large specific surface area and a greater potential for ionization. 
Neither genotoxicity nor in vivo toxicity was observed in our experimental conditions. 
However, we suggest long-term monitoring is need for nanocalcium due to their 
differential of ionization derived from their different specific surface area. 
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1) Application of nanotechnology  
Scientific technology of 21st century is considered to be led by nanotechnology. 
Nanotechnology is driving the creation of a myriad of novel materials with many 
applications in disciplines as diverse as medicine, electronics, biomaterials and the 
food industry. Applications of nanotechnology make revolution in the food industry 
including improvement of taste, flavor, color, safety and food packaging. Global 
market value of nanofood applications including food packaging was estimated at 
US$4 million in 2006, predicted to range between US$6 billion by 
2012(Cientifica,2006) and more than 20 billion by 2010 (Helmut Kaiser Consultancy, 
2004).  
Reducing the particle size of materials may be an efficient and reliable tool for 
improving the bioavailability and absorption in food. Indeed, nanonization of the 
particles improved absorption rate of drug or nutrients in human (Liversidge and 
Cundy 1995; Merisko-Liversidge and Cooper 2003; Douroumis and Fahr 2006). Since 
the application of nanotechnology to health food science to stabilize bioactive 
materials and improve their bioavailability (Mozafari et al., 2008), various trials had 
sought to enhance the capabilities of nanotechnology in food, for example, in 
overcoming the limitations of absorption efficiency of specific essential components. 
Coming into the market nanoparticulate additives or supplements such as calcium, 
magnesium, iron, zinc, omega-3 fatty acid, lycopene, Vitamin D2 and beta-carotene 
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shows application of nanotechnology for healthfood. 
2) Efficacy of nanocalcium  
Calcium is essential for living organisms, in particular for the cell physiology, where 
calcium influx and efflux functions as a signal for many cellular processes. As a major 
material used in mineralization of bone, teeth, calcium is the most abundant metal by 
mass in many animals. Calcium deficiency leads to osteoporosis.   
Despite its physiological significance, the absorption efficiency of calcium is 
difficult to enhance. Various studies have sought to improve the absorption efficiency. 
Some recent study showed nanocalcium improved absorption efficiency and 
bioavailability. Park et al., (2008) compared the effect of nanocalcium to other calcium 
form and reported that consumption of nanocalcium enriched milk resulted in 
increasing the urinary excretion of calcium, while decreasing that of deoxypyridinoline 
and hydroxyproline in ovary ectomized (OVX) rats. The study suggests that nano-
calcium enriched milk effectively promotes bone formation in OVX rats. Huang et al 
(2009) showed that nanocalcium carbonate and nanocalcium citrate is more 
bioavailable than microcalcium carbonate and microcalcium citrate, respectively. 
Nano-sized calcium is expected to be easily absorbed into the body due to the large 
surface area (Hu et al., 2010). Also, Chen et al.,(2008) showed nanonized peal powder 
improves bioavailability and absorption of calcium compare with micronized peal 
powder. The collective data have demonstrated that nanocalcium is more effective by 
virtue of the increased of the surface area.  
3) Potential toxicological effect of nanomaterials 
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Whereas potential benefits of nanoproducts are emphasized, potential toxicological 
effects of nanomaterials are little known. Nanoparticles may appear toxicological 
effect on biological system even if bulk materials of the same composition dose not 
shown toxicity (Nel et al., 2006; Oberdorster et al., 2005). Due to increased surface 
area, nanomaterials have highly reactive characteristic which potentially could lead to 
toxicity (Oberdorster et al., 2005). Applerot et al. (2009) and Hanley et al. (2009) 
showed ZnO nanomaterials are more toxic than macro-sized ZnO particles. Chen et al. 
(2006a, 2006b) determined the acute toxicity of copper particles and nanocopper in 
mice and found that nanocopper was more toxic than bulk copper. Used nano-sized 
particles for food may have different properties from macro-sized particles that 
influence on our bodies.  
4) Need for safety evaluation of nanocalcium  
Toxicologically, it has been premature to conclude that nanocalcium is relatively 
more toxic than larger-sized calcium. Huang et al. (2009) estimated calcium carbonate 
and calcium citrate in both the nano and micro form in vitro and in vivo using ICR 
mice. But, for calcium carbonate, the concentration of high dose group was insufficient 
to assess toxicity. In OECD Test Guideline, the concentration of the high dose group 
was recommended as 2,000 mg/kg. Hu et al. (2010) showed that polyacrylic acid 
(PAA) can provide a more biologically friendly pathway to prepare biological 
nanocalcium phosphate for biomedical applications by assessing the viability of bone 
marrow mesenchymal stem cells (BMSCs) in vitro. In this report, in vivo toxicity was 
not assessed, not was the effect on normal cell lines. Park et al. (2008) also did not 
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provide sufficient data to draw any conclusion about the toxicity of nanocalcium. 
Genotoxicity and in vivo toxicity test data are lacking, but are essential to estimate the 
toxicity of nanocalcium.  
Also, it is important to estimate the toxicity of nanocalcium based on physico-
chemical properties. In general, nanomaterials including nanocalcium have several 
attributes: (1) nanoparticles are more chemically reactive than larger particles because 
of their increased surface area; (2) nanoparticles have greater access to our bodies than 
larger particles; (3) the enhanced bioavailability and bioactivity of nanoparticles may 
introduce new and unknown toxicity; (4) nanoparticles may be capable of disrupting 
immune responses; and (5) nanoparticles may have long-term pathological effects 
because of their low excretion rate (Oberdörster et al., 2005; Nel et al., 2006; Chithrani 
et al., 2006; Sonavane et al., 2008). In this study, nano- and microcalcium were 
compared in terms of their physico-chemical properties to estimate the genotoxicity 
and in vivo toxicity of nanocalcium. The goal was to productively contribute to 
determining the maximum concentration of nanocalcium in a 13-week oral repeated 




MATERIALS AND METHODS 
 
Blind test and selection of nanocalcium and microcalcium 
After the blind test for seven samples provided from Korea Food and Drug 
Administration (KFDA), we selected nanocalcium and microcalcium based on their 
size and purity. Both type of particles were provided at >98.0% purity. The powders 
were stored at room temperature until analysis.  
 
Characterization of nano- and microcalcium 
 
Measurement of size of nanocalcium and microcalcium  
High resolution images were obtained by energy-filtering transmission electron 
microscopy (EF-TEM) using a LIBLA 120 microscope (Carl Zeiss, Oberkochem, 
Germany) at an accelerating voltage of 120 kV. A dilute suspension (4 mg/ml) of 
particles was prepared in methanol and sonicated for 30 s. A portion of the aqueous 
dispersion was deposited on a 300-mesh carbon-coated copper grid and dried at room 
temperature overnight before examination. To demonstrate the morphology and size of 
the particles, the samples were examined by field-emission scanning electron 
microscopy (FE-SEM) using a SUPRA 55VP instrument (Carl Zeiss) operating at 15 
kV. For FE-SEM, samples were placed on conductive copper tape and analyzed. The 
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electrical conductivity of the samples was enhanced by coating them with platinum via 
sputtering (BAL-TEC, Witten/Ruhr, Germany) before examination. 
 
X-ray diffractometry (XRD) 
XRD was conducted using a D8 Advence (Bruker, Rheinstetten, Germany) 
investigate the crystal structure of nano- and microcalcium particles. Samples of about 
1 g in weight were placed onto an aluminum holder. The goniometer was motorized 
and moved through a range of θ–2θ mode scan. The diffractometer was run at 40 kV 
and 40 mA in the range of 20–80 °. Steps were increments of 0.02 °, and counts were 
collected for 2 s at each step.  
 
Dynamic light scattering (DLS) measurements  
Particle size and distribution of nanocalcium and microcalcium were determined 
using an ELS-8000 electrophoretic light scattering spectrophotometer (Photal, Osaka, 
Japan) based on the DLS principle. For these measurements, 4 ml of a 0.2 mg/ml 
suspension of particles in methanol was ultra-sonicated for 30 s. To determine particle 
size and distribution, each particle suspension was measured at 30 the number of 
circuits at room temperature.  
 
Measurement of specific surface area 
Specific surface area of nanocalcium and microcalcium particles was determined by 
the N2 Brunauere Emmette Teller (BET) method using a BELSORP-max (MP) 
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analyzer (BEL, Osaka, Japan). Dried and degassed samples were analyzed using a 
multipoint N2 adsorption-desorption method at room temperature (Streppel et al., 
2011; Brunauer et al., 1938).  
 
Electron spin resonance (ESR) spectroscopy and spin-trapping 
measurements 
ESR signals of samples were taken using a JES-TE200 ESR spectrometer (JEOL, 
Tokyo, Japan) with a X-band standard frequency of 8.8–9.6 GHz. To identify the peaks, 
the signal components were analyzed by the ES-IPRITS DATA SYSTEM, Version 3.00 
analysis software installed in the ESR instrument (ESR computer software. ESR 
spectra were measured for 2 min after the introduction of nano- or microcalcium. The 
electronic measurement conditions were: frequency 9.42 GHz, mod 100 kHz, time 
constant 0.03 s, and power 5.00 mW. Aqueous samples were loaded into a LC-12 
aqueous quartz flat cell (JEOL). To detect •OH (hydroxyl) and 1O2 (singlet oxygen) 
radicals in a water suspension of nanocalcium and microcalcium (10 mg/ml), the ESR 
spin-trapping technique was designed. Spin-trap agents and scavengers used in this 
study were 5,5-dimethyl-1-pyrroline N-oxide (DMPO) for •OH and 2,2,6,6-
tetramethylpiperidine (TEMP) for 1O2.  
 
Ca2+ release from nano- and microcalcium particles 
Inductively coupled plasma optical emission spectrometry (ICP-OES) was carried 
out using an ICP-730 ES apparatus (Varian, California, USA). ICP-OES is a sensitive 
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means of determining both the presence of metal analytes and their concentrations. To 
confirm the release of Ca2+ from nano- and microcalcium particles, the pH-dependent 
release of Ca2+ was analyzed. The concentration of nano- and microcalcium particles 
suspended in solution for testing was determined at 10 mg/ml and samples were 
measured after suspension in solution for 6 h. The pH of the solvents was 2, 5, and 7. 
 
Genotoxicity of nanocalcium 
 
Chromosomal aberration test 
This test was performed according to OECD Test Guideline No. 473 (OECD, 1997). 
Chinese hamster ovary fibroblasts cells (CHO-k1) were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in F-12 medium 
supplemented with 10% fetal bovine serum, penicillin (100 IU/ml), and streptomycin 
(100 mg/ml) at 37 oC in a humidified atmosphere of 5% CO2. CHO-k1 cells were 
exposed to nanocalcium particles for a short-term (6 h) and long-term (24 h). 
Mitomycin C (direct method) and cyclophosphamide (metabolic activation method) 
were used as the positive control substance. The cytotoxicity test was expressed as 
growth inhibition 50% (GI50) by calculating the probit. To make chromosome slides, 
the harvested cultures were incubated with a 0.075 M KCl for 20 min. The cells were 
fixed in a methanol / glacial acetic acid solution 3 : 1 (v/v). This step was repeated 
three times and the cells were dropped onto a slide. After air drying, the cells were 
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stained with 5% Giemsa (Merck, Darmstadt, Germany) solution. At least two slides 
were generated per culture and 200 metaphase events were analyzed per concentration. 
 
Micronucleus assay 
This study was performed in accordance with OECD Test Guideline 474 (OECD, 
1997). Seven-week-old male ICR mice were purchased from ORIENT BIO 
(Gyeonggi-do, Korea). Only healthy animals were selected for this study by 
observation of the absence of general symptoms for 7 days of the acquisition. 
Nanocalcium was administrated orally using a sonde. The positive control substance 
was administered intraperitoneally to test animals using a disposable 26G syringe. 
According to the preliminary study result, the highest dose was determined to 2000 
mg/kg. Test groups were consisted of five groups (n=6 animals per group): negative 
control group (distilled water), three dose groups (500 mg/kg, 1000 mg/kg, and 2000 
mg/kg), and one positive control group (Mitomycin C (MMC), 2.0 mg/kg). Bone 
marrow smears were done 24 h after administration by staining with acridine orange or 
4% Giemsa solution. The number of micronucleated polychromatic erythrocytes 
(MNPCEs) per 2000 PCEs for each mouse was counted at 400-fold magnification 
using a fluorescence microscope (Leica, Wetzlar, Germany). The ratio of PCEs to 
normochromatic erythrocytes [i.e., PCE / (PCE+NCE)] was calculated based on a total 
of 200 erythrocytes at 1000-fold magnification (Carl Zeiss). Statistical analyses were 
performed using SPSS 12.0 (SPSS, Chicago, IL, USA) and the data was expressed as 
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the mean ± SD. One-way analysis of variance (ANOVA) was applied to the 
micronucleus test all the data. A value of p < 0.05 indicated statistical significance. 
 
Bacterial reverse mutation assay 
In this study, we used Salmonella typhimurium strains TA98, TA100, TA1535, and 
TA1537 and Escherichia coli WP2uvrA (Molecular Toxicology, Boone, NC, USA). 
This study was conducted using a pre-incubation method in the presence and absence 
of metabolic activation, according to the OECD Test Guideline 471 (OECD, 1997). 
The test substance, nanocalcium, was supplied from KFDA and was dispersed in 
distilled water. The strains were cultured in Oxoid nutrient broth No. 2 for 10 h at 37 oC 
with shaking. After culture, strains were added to different concentration (0, 313, 625, 
1250, 2500, and 5000 µg/plate) of nanocalcium, which were dispersed in 50 µl distilled 
water and 0.5 ml S9 mixture (or sodium phosphate buffer). They were incubated in 
shaking water bath at 100 rpm rotating speed and at 37 oC for 20 minutes. Two 
milliliters top agar were added and poured onto glucose minimal agar plate. Plates 
were incubated in vented incubator at 37 oC for 48 h. After that, the number of revertant 
colonies was counted. If there was over 2-fold increase of the negative control value or 
dose-dependent increase in the number of revertants in one or more strains, a decision 
was made on the mutagenecity. The study was performed twice (preliminary-dose 
finding and main study) with triplicate determinations at each dose level.  
 




This test was performed in accordance with KFDA Notification No. 2009-116 
(Toxicity Test Standards of Medicine and Medical Supplies, Revised August 24, 2009). 
The test substance, nanocalcium, was supplied from KFDA and was dispersed in 
distilled water. Seven-week-old male and female, specific-pathogen free (SPF) 
Sprague-Dawley (SD) rats supplied from ORIENT BIO were acclimated for 7 days 
before administration. During the acclimation and experimental periods, the rats were 
housed in stainless wire mesh cages (maximum of three rats per cage) in a room with 
controlled temperature (22.3 ± 0.6 oC) and humidity (55.7 ± 2.4% relative humidity), 
and a 12-h light/dark cycle. The rats were fed a rodent diet (Harlan Teklad, Madison, 
Wisconsin, USA) and filtered water ad libitum. There were four groups consist of 10 
animals (five females and five males) at each dose level: vehicle control (distilled 
water), low-dose (500 mg/kg), middle-dose (1,000 mg/kg), and high-dose (2,000 
mg/kg). When the rats were 8-weeks-of-age, they were exposed to nanocalcium by 
gavage at a dose of 20 ml/kg. For 14 days, clinical signs and mortalities of all animals 
were observed once a day and the body weight were measured four times (before 
administration and on days 1, 7, and 14 after administration). On day 14, all surviving 
animals were anesthetized with CO2 gas and killed by exsanguination from the aorta. 
Complete post-mortem examinations were performed on all vital organs.  
 
Repeated-dose 14-day oral toxicity test  
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This test was performed in accordance with KFDA Notification No. 2012-86 
(Toxicity Test Standards of Medicine and Medical Supplies, Revised August 24, 2012) 
and OECD Test Guidelines 407 (OECD, 1998). The test substance, nanocalcium, was 
supplied by KFDA and was dispersed in distilled water. Five-week-old male and 
female, SPF SD rats supplied from ORIENT BIO were acclimated for 7 days before 
administration. During the acclimation and experimental periods, the rats were housed 
in stainless wire mesh cages (maximum of three rats per cage) in a room with 
controlled temperature (21.6 ± 1.2 oC) and humidity (56.6 ± 8.5% relative humidity) 
and a 12-h light/dark cycle. The rats were fed a rodent diet (Harlan Teklad) and filtered 
water ad libitum. There were four groups (n=10 per group; five females and five 
males) at each dose level: vehicle control (distilled water), low-dose (500 mg/kg), 
middle-dose (1,000 mg/kg), and high-dose (2,000 mg/kg). When the rats were 6-
weeks-of-age they were exposed to nanocalcium by gavage. The total dosing volume 
was 20 ml/kg but it was administrated twice a day by dividing the total dosing into two 
10 ml/kg in 1-2 h intervals. For 14 days, clinical signs and mortalities of all animals 
were observed twice a day just after administration. The body weight and food 
consumption were measured once a week. One week after the administration, the eye 
examination and urinalysis were performed using a CliniTek 50 (SIEMENS, Berlin, 
Germany). The urinalysis included the following inspection items: glucose, 
urobilinogen, bilirubin, nitrite, ketone body, leukocyte, specific gravity, protein, occult 
blood, and pH. At the end of the study, rats fasted one night before the necropsy were 
anesthetized with CO2 gas and a blood sample was collected from the abdominal aorta 
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just prior to killing each animal. They were analyzed for hematology using an ADVIA 
2120 apparatus (SIEMENS, Berlin Germany) and a model 7180 clinical biochemistry 
instrument (Hitachi, Hitachi, Japan). Inspection items in hematology were white blood 
cells (WBC), red blood cells (RBC), hemoglobin (Hb), Hematocrit (HCT), Mean 
corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH) Mean corpuscular 
hemoglobin conc. (MCHC), Red cell distribution width (RDW), Platelet (PLT), Mean 
Platelet Volume (MPV), differential count, Large unstained cells (LUC), and 
reticulocytes. Inspection items in clinical biochemistry were aspartate transaminase 
(AST), alanine transaminase (ALT), alkaline phosphatase (ALP), Gamma(γ)-glutamyl 
transferase (GGT), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), 
creatinine, glucose, total cholesterol, total protein, creatine phosphokinase, Albumin 
(ALB), total bilirubin, Albumin / Globulin (A/G) ratio, triglyceride, uric acid, calcium 
(Ca), Inorganic phosphorus (IP), chloride (Cl), magnesium (Mg), sodium (Na), and 
potassium (K). Each rat was terminated by exsanguination and subjected to a full 
necropsy with complete post-mortem examinations. The extracted organs were 
weighed using an electronic balance. Finally, the histopathological examination was 
conducted for abnormal organs.  
 
Statistical analyses  
 
The differences among the vehicle control and the dosing groups were examined 
using SPSS for Windows version 12.0 software (SPSS, Chicago, IL, USA). Continuous 
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data (body weights, food consumption, hematology, blood biochemistry, and organ 
weights) were analyzed to analyzed supposing that the distribution is normal. 
Differences among the groups were examined and equal variance was ascertained 
using the standard one-way analysis of variance (ANOVA). If these tests showed 
statistical significance, the data were analyzed using the multiple comparison 
procedure. While, non-continuous data (urinalysis) were converted by scale conversion 






Characterization of nano- and microcalcium  
The size of nano- and microcalcium were determined using ed EF-TEM and FE-
SEM. Representative EF-TEM images of nanocalcium and microcalcium are shown in 
Figures 1A and 1B, respectively. While the average particle sizes could not be 
determined, nanocalcium particle diameter ranged from 50 nm to 1 μm. The diameter 
of microcalcium ranged from 1 μm to 10 μm. EF-TEM also revealed variously sized 
agglomerations of nano- and microcalcium particles. FE-SEM was carried out to 
observe the surface shape of agglomerated and non-agglomerated calcium. 
Nanocalcium particles over 100 nm in diameter featured a crystalline agglomerate core 
(Figure 2A-1), while smaller diameter particles had a non-crystalline portion bonded 
on the core calcium (Figure 2A-2). Nanocalcium particles developed for use as dietary 
supplements were agglomerated, so determination of their mean size with EF-TEM and 
FE-SEM was not feasible. DLS also was not useful in size determination (Figure 3). 
Nanocalcium particles featured two size groups, one from 200–500 nm and the other 
exceeding 500 nm. Microcalcium particles ranged from 1.5–30 µm, with many 
subgroups evident. XRD analysis revealed common aspects of component properties 
between nano- and microcalcium. Both particle types were single-phased calcium 
carbonate (CaCO3) with a calcite structure (Figure 4), despite the differing surface 
morphology and inability to determine average size. Moreover, the specific surface 
area could not be reliably determined for agglomerated samples. For agglomerates, the 
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expected number of particles with a specific surface area was disparate; the increase of 
surface area was smaller than expected for agglomerated particles due to the decrease 
of their size in the same mass. For safety determinations of nanomaterials, including 
nanocalcium, it is important to provide information related with size and concentration. 
To overcome these limitations in the agglomerated samples, the BET method was tried. 
The specific surface area of nanocalcium and microcalcium was 12.90 ± 0.27 m2/g and 
1.12 ± 0.19 m2/g, respectively. The surface area of nanocalcium particles exceeded that 





Figure 1 | Energy-filtering transmission electron microscopy images of 
nanocalcium (A) and microcalcium (B). Nano- and microcalcium particles were 
polygonal in shape. Particle size varied widely. The diameter of nanocalcium particles 







Figure 2 | Field-Emission scanning electron microscopy images of nanocalcium 
(A) and microcalcium (B) particles. The diameter of nanocalcium particles ranged 




Figure 3 | Dynamic light scattering analysis of (A) nanocalcium and (B) 
microcalcium particles. The left, middle, and right panel displays intensity, volume, 
and number in each sample, respectively. 
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1.1221 ± 0.1938 m2/g 
 














ESR spectroscopy and spin-trapping measurements 
To detect reactive oxygen species (ROS) from the surface of nanocalcium, ESR 
signals corresponding to the physicochemical characteristics were analyzed. Hydroxyl 
radical signal measured using 50 mM DMPO was not detected. Singlet oxygen 
measured using 4.7 mM TEMP displayed a unique 1:1:1 pattern, but was not 
appreciably different from the distilled water control. As shown in Figure 5, no ESR 
signals were evident in nano- and microcalcium samples, indicating the lack of ROS on 






Figure 5 | Electron spin resonance analysis of nanocalcium (upper line), 
microcalcium (middle line), and control (lower line) in detection of hydroxyl 
radial (A) and singlet oxygen (B). Hydroxyl radial was analyzed using a spin-trap 
agent (50 mM DMPO). Singlet oxygen was analyzed using another spin-trap agent (4.7 




Ca2+ release from nano- and microcalcium particles 
Ca2+ release from nano- and microcalcium particles was assessed using ICP-OES. 
Table 2 summarizes the concentrations of Ca2+ detected at the various pHs. At pH 2, 
there was no critical difference in the release of Ca2+. However, at pH 5 and pH 7, the 
Ca2+ released from nanocalcium exceeded that from microcalcium by 2–3 times.  
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Table 2. Concentration of Ca2+ released from nano- and microcalcium particles in 
various solvent for 6 h. 
Sample Solvent 
Test concentration 
of CaCO3 (mg/ml) 
Release of Ca2+(μg/ml, n = 3) 
Concentration ± S.D. 
Solvent 
pH 2 
0  0.058 ± 0.006 
Nanocalcium 10  593.333 ± 22.038 
Microcalcium 10  564.533 ± 26.530 
     
Solvent 
pH 5 
0  0.024 ± 0.003 
Nanocalcium 10  16.747 ± 0.081 
Microcalcium 10 7.344 ± 0.077 
     
Solvent 
pH 7 
0  0.000 ± 0.000 
Nanocalcium 10  15.860 ± 0.105 
Microcalcium 10  5.560 ± 0.077 
Ca2+ content of CaCO3 materials was determined by inductively coupled plasma 










Genotoxicity of nanocalcium 
In the chromosome aberration test, nanocalcium did not produce a statistical 
increase in the number of cells, when compared to conditions with or without 
metabolic activation. Furthermore, in the presence and absence of the S9 mix, 
nanocalcium did not induce a statistically significant increase in the number of cells 
with polyploidy or endoreduplication when compared with the negative control group 
(Table 3). In an in vivo micronucleus assay, nanocalcium did not induce a significant 
increase in MNPCEs at 500 mg/kg, 1000 mg/kg, and 2000 mg/kg, as compared to the 
negative control group (Table 4). Furthermore, there was no significant decrease in the 
PCE / (PCE+NCE) ratio, which is an indicator of cytotoxicity. No abnormalities were 
evident at any concentration of administered nanocalcium. Body weight did not differ 
significantly between treated and negative control groups (data not shown). As 
expected, MNPCEs in the positive control group were significantly increased 
compared to the negative control (P<0.01), confirming the validity of the experiment. 
In the bacterial reverse mutation assay, growth inhibition was not observed in any dose 
level and strain regardless of metabolic activation (Table 5). There was no significant 
increase in the number of revertant colonies when compared to the negative control in 
all bacterial strains both with and without metabolic activation. These results support 
the view that nanocalcium does not produce severe genotoxicity under the 
experimental conditions.  
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Table 3. Chromosome aberrations test of nanocalcium in Chinese hamster ovary 
fibroblasts in the absence or presence of S9 mix. 
* Significantly different from the negative control at P<0.05 
a Treatment time-recovery time  
MMC: Mitomycin C (0.04 μg/ml) 
PP: Polyploidy  
ER: Endoreduplication  








No. of total chromosome 
aberrations (mean) 
No. of cells with  
chromosome 
aberrations (mean) PP+ER 
(Mean) 
(-)Gap (+)Gap (-)Gap (+)Gap 
24-0 - Negative control 0.5 0.5 0.5 0.5 0 
 - 39.06 0.5 1.5 0.5 1.5 0 
 - 78.13 0.5 1 0.5 1 0 
 - 156.25 1 1.5 1 1.5 0 
 - MMC (0.04) 26.5 26.5 26 * 26 0 
6-18 - Negative control 0 0 0 0 0 
 - 39.06 1 1.5 1 1.5 0 
 - 78.13 0.5 0.5 0.5 0.5 0 
 - 156.25 0.5 1 0.5 1 0 
 - MMC (0.04) 24 24 24 * 24 0 
6-18 + Negative control 0.5 0.5 0.5 0.5 0 
 + 78.13 0.5 0.5 0.5 0.5 0 
 + 156.25 1 1 1 1 0 
 + 312.5 1.5 1.5 1.5 1.5 0 
 + CPA (10) 26.5 26.5 26.5 * 26.5 0 
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Vehicle control 0 0.23 ± 0.15 0.42 ± 0.08 
nanocalcium 
500 0.15 ± 0.11 0.49 ± 0.11 
1000 0.29 ± 0.10 0.52 ± 0.06 
2000 0.21 ± 0.14  0.56 ± 0.04 * 
MMC 2.0  9.02 ± 0.66 ** 0.37 ± 0.03 
Vehicle: distilled water 
* Significantly different from the control at P<0.05 (One-way ANOVA) 
** Significantly different from the control at P<0.01 (One-way ANOVA)  
MNPCE: PCE with one or more micronuclei 
PCE: Polychromatic erythrocyte 
NCE: Normochromatic erythrocyte 




Table 5. Bacterial reverse mutation test of nanocalcium in the absence or presence 





Number of colony / plate (Mean ± SD) 
TA98 TA100 TA1535 TA1537 WP2uvrA 
S9 
mix (-) 
0 20±1.2 95±8.3 7±1.7 4±2.0 54±3.1 
313 24±2.6 74±4.6 6±0.6 3±0.6 50±7.6 
625 18±2.5 79±0.6 7±3.2 4±1.5 47±4.0 
1250 18±1.5 70±1.5 4±0.0 6±1.5 51±6.8 
2500 20±3.1 63±1.5 5±1.5 5±1.5 46±4.4 
5000 † 19±1.0 64±3.2 7±1.0 5±1.0 34±4.0 
Positive 549±78.5a 760±104.6b 265±62.0c 2207±197.4d 245±37.8 b 
S9 
mix (+) 
0 23±2.5 94±2.6 7±2.0 8±1.2 56±6.2 
313 24±5.0 103±12.1 10±2.1 10±1.5 49±1.0 
625 21±3.6 108±3.1 8±2.0 8±2.5 54±1.0 
1250 23±4.4 94±5.9 9±2.9 12±3.2 47±8.7 
2500 23±1.5 93±3.5 7±2.6 11±2.1 53±9.9 
5000 22±1.5 100±11.8 7±2.6 10±1.5 43±10.6 
Positive 351±32.1 e 995±48.9 f 183±15.0 g 252±58.9 h 344±34.9 g 
a Positive control was 0.1 ㎍/plate of 2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide 
b Positive control was 0.01 ㎍/plate of 2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide 
c Positive control was 0.5 ㎍/plate of Sodium azide 
d Positive control was 80 ㎍/plate of 9-Aminoacridine hydrochloride hydrate 
e Positive control was 0.5 ㎍/plate of 2-Aminoanthracene 
f Positive control was 1 ㎍/plate of 2-Aminoanthracene 
g Positive control was 2 ㎍/plate of 2-Aminoanthracene (Continue-next page) 
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h Positive control was 10 ㎍/plate of 2-Aminoanthracene 
 
†: test substance precipitation 
 
Single-dose acute oral toxicity 
Lethal dose 50 (LD50) and oral toxicity of nanocalcium were determined in 
Sprague-Dawley rats at doses of 500 mg/kg (low-dose), 1,000 mg/kg (middle-dose) 
and 2,000 mg/kg (high-dose), and compared with vehicle control group. Mortality, 
clinical signs, body weight, and necropsy findings were determined. Mortalities and 
unusual clinical signs were not observed and there were normal body weight gains in 
all animals (data not shown). Necropsy revealed no abnormal gross findings. The 
collective data indicate that under the conditions of this study, the single-dose acute 
oral LD50 of nanocalcium can exceed 2,000 mg/kg body weight.  
 
Repeated-dose 14-day oral toxicity test 
This study was performed to evaluate the 14-day oral repeated dose toxicity and 
determine the dose levels for 13-week oral repeated dose toxicity of nanocalcium in 
Sprague-Dawley rats using doses of 0 (vehicle control), 500 (low dose), 1,000 (middle 
dose), and 2,000 (high dose) mg/kg. Mortality, clinical signs, body weight change, food 
consumption, eye examination, urinalysis, hematology, blood biochemistry, necropsy, 
organ weights, and histopathological findings were examined. No deaths or unusual 
clinical signs were evident. There were no significant differences among groups in 
most of the tested parameters, such as body weights (Figure 6), food consumptions 
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(data not shown), urinalysis (data not shown), hematology (Table 6), blood chemistry 
(Table 7), and organ weights (Table 8). Especially, there was no critical difference in 
Ca2+ level in the nanocalcium treated rats. Significant differences were observed in 
food consumption and some aspects of hematology (percentage of neutrophils and 
percentage of lymphocytes), but they were considered to be unrelated with the applied 
test substance. Necropsy findings included focal nodule of spleen, small left testis, and 
adrenal in male rats receiving the dose of 2,000 mg/kg. They were considered as focal 
increased cellularity of white pulp at kidney, unilateral atrophy/immature at testis, and 
unilateral aplasia at adrenal in histopathological examination. However, these changes 
were likely unrelated with the test substance and were considered to be incidental or to 
have occurred congenitally. Under the conditions of this study, there were no 
toxicological significances related to the test substance. OECD Test Guideline 408 
(OECD, 1998) suggests 1,000 mg/kg as the limited dose level on repeated dose toxicity 
test. On the basis of the present results, 1,000 mg/kg is recommended as the high dose 





Figure 6 | Body weight changes of male (A) and female (B) rats orally treated with 
nanocalcium for 14 days. Body weight was measured 1st week and 2nd week. Each 



















0 500 1,000 2,000 
MALE Mean ± S.D. 
WBCa (K/μl) 7.00 ±0.63  8.02 ±1.35  10.06 ±1.84  8.34 ±3.66  
NEb (K/μl) 0.84 ±0.18  1.25 ±0.46  0.97 ±0.18  1.32 ±0.56  
LYc (K/μl) 5.95 ±0.70  6.56 ±1.31  8.84 ±1.61  6.75 ±2.97  
MOd (K/μl) 0.12 ±0.03  0.13 ±0.03  0.13 ±0.05  0.15 ±0.08  
EOe (K/μl) 0.04 ±0.02  0.03 ±0.01  0.04 ±0.01  0.05 ±0.03  
BAf (K/μl) 0.00 ±0.01  0.01 ±0.01  0.01 ±0.00  0.01 ±0.01  
NEPg (%) 12.1 ±3.3  15.8 ±5.6  9.6* ±0.8  15.9 ±1.4  
LYPh (%) 84.8 ±3.7  81.7 ±5.8  87.9* ±0.5  81.1 ±1.7  
MOPi (%) 1.7 ±0.5  1.6 ±0.3  1.3 ±0.4  1.8 ±0.5  
EOPj (%) 0.6 ±0.2  0.4 ±0.2  0.3 ±0.1  0.6 ±0.2  
BAPk (%) 0.1 ±0.1  0.1 ±0.1  0.1 ±0.0  0.1 ±0.0  
RBCl (M/μl) 7.18 ±0.37  7.17 ±0.27  6.93 ±0.29  7.03 ±0.34  
Hbm (g/dl) 15.0 ±0.7  14.7 ±0.5  14.4 ±0.4  14.4 ±0.8  
HCTn (%) 47.1 ±2.5  46.6 ±0.5  45.8 ±1.3  45.2 ±2.9  
MCVo (fl) 65.5 ±1.2  65.1 ±3.0  66.0 ±2.9  64.3 ±1.8  
MCHp (pg) 20.9 ±0.4  20.6 ±0.6  20.8 ±0.9  20.5 ±0.6  
MCHCq (g/dl) 31.9 ±0.5  31.6 ±1.1  31.5 ±0.4  31.8 ±0.9  
RDWr (%) 11.6 ±0.3  11.9 ±0.6  11.9 ±0.2  11.7 ±0.4  
PLTs (K/μl) 1367 ±128  1457 ±164  1363 ±138  1337 ±176  
MPVt (fl) 9.1 ±0.3  9.1 ±0.2  9.1 ±0.2  9.1 ±0.3  
LUCu (%) 0.06 ±0.02  0.05 ±0.03  0.07 ±0.04  0.06 ±0.04  
Retiv (%) 4.4±0.4 5.1±1.5 4.5±0.2 4.2±0.4 
FEMALE Mean ± S.D. 
WBCa (K/μl) 6.38±2.04  8.67±2.46  7.54±4.01  5.81±1.28  
NEb (K/μl) 0.63±0.26  0.67±0.16  0.64±0.38  0.50±0.20  
LYc (K/μl) 5.53±1.80  7.71±2.28  6.67±3.64  5.10±1.13  
MOd (K/μl) 0.10±0.02  0.12±0.06  0.14±0.09  0.11±0.02  
EOe (K/μl) 0.05±0.02  0.06±0.02  0.04±0.01  0.03±0.02  
BAf (K/μl) 0.00±0.01  0.00±0.01  0.00±0.00  0.01±0.01  
NEPg (%) 10.0±2.7  8.2 ±2.5  8.5±2.3  8.6±2.7  
LYPh (%) 86.6±2.4  88.5±2.4  88.4±3.2  87.8±2.9  
MOPi (%) 1.6±0.3  1.4±0.5  1.8±0.7  2.0±0.3  
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EOPj (%) 0.7 ±0.4  0.7±0.2  0.5±0.2  0.4±0.3  
BAPk (%) 0.1±0.1  0.1±0.1  0.1±0.1  0.1±0.1  
RBCl (M/μl) 7.21±0.42  6.93±0.45  6.92±0.20  7.20±0.48  
Hbm (g/dl) 14.5±0.5  14.3±0.5  14.4±0.6  14.9±1.1  
HCTn (%) 44.2±2.1  42.4±2.1  43.3±2.5  45.3±3.7  
MCVo (fl) 61.3±2.5  61.3±2.1  62.5±2.1  62.9±2.5  
MCHp (pg) 20.1±0.8  20.7±1.0  20.9 ±0.5  20.7±0.8  
MCHCq (g/dl) 32.9±0.5  33.8±0.7  33.4±0.6  33.0±0.7  
RDWr (%) 10.8±0.1  11.1±0.5  10.7±0.3  11.1±0.4  
PLTs (K/μl) 1459±189  1359±248  1608±332  1472±194  
MPVt (fl) 8.9±0.3  8.7±0.5  9.0±0.8  9.2±0.7  
LUCu (%) 0.07±0.04  0.10±0.05  0.06±0.03  0.06±0.02  
Retiv (%) 2.8±0.5 3.0±0.2 2.7±0.5 2.7±0.7 
Each group consisted of five animals of both sexes. Values are mean±standard deviation. *Significant 
difference compared with 2,000 mg/kgvalue, P<0.05. a: White blood cell, b: Neutrophils, c: Lymphocyte, 
d: Monocyte, e: Eosinophil, f: Basophil, g: Percent of neutrophils, h: Percent of lymphocyte, i: Percent of 
monocyte, j: Percent of eosinophil, k: Percent of basophil, l: Red blood cell, m: Hemoglobin, n: 
Hematocrit, o: Mean corpuscular volume, p: Mean corpuscular hemoglobin, q: Mean corpuscular 
hemoglobin concentration, r: Red cell distribution width, s: Platelet, t: Mean platelet volume, u: Large 
unstained cell, v: Reticulocyte 
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0 500 1,000 2,000 
MALE Mean ± S.D. 
ASTa (IU/l) 157 ±21  144 ±19  165 ±29  149 ±25  
ALTb (IU/l) 32 ±2  34 ±4  43 ±11  35 ±5  
ALPc (IU/l) 941 ±231  840 ±136  876 ±125  797 ±213  
GGTd (IU/l) 0.0 ±0.0  0.0 ±0.0  0.2 ±0.4  0.2 ±0.4  
LDHe (IU/l) 1811 ±492  1447 ±479  1716 ±703  1550 ±452  
BUNf (㎎/dl) 14.0 ±1.8  14.0 ±0.6  13.5 ±1.3  13.9 ±1.6  
CREg (㎎/dl) 0.42±0.06 0.42±0.03 0.40±0.03 0.41±0.03 
GLUh (㎎/dl) 130±14  150 ±50  141 ±33  144±24  
CHOi (㎎/dl) 84±10  70 ±16  88 ±22  70 ±21  
TPj (g/dl) 5.6 ±0.2  5.6 ±0.1  5.4 ±0.2  5.5 ±0.2  
CPKk (U/l) 1114 ±306  969 ±228  1125 ±422  1086 ±371  
ALBl (g/dl) 2.4 ±0.1  2.4 ±0.0  2.3 ±0.0  2.4 ±0.1  
T-BILm( mg/dl) 0.04±0.01 0.03±0.01 0.02±0.01 0.02±0.02 
A/G ration  0.74±0.03 0.74±0.04 0.72±0.06 0.76±0.03 
TGo (㎎/dl) 42 ±12  45 ±16  51 ±16  47 ±12  
UAp (㎎/dl) 2.8 ±1.1  2.4 ±0.9  2.5 ±0.4  2.5 ±0.5  
Caq (㎎/dl) 10.7 ±0.2  10.4 ±0.7  10.5 ±0.2  10.3 ±0.5  
IPr(㎎/dl) 11.1 ±0.8  10.8 ±0.7  10.9 ±0.8  11.2 ±1.2  
Cls (mmol/l) 106 ±1  105 ±2  106 ±2  106 ±2  
Mgt (㎎/dl) 2.8 ±0.6  2.7 ±0.3  2.6 ±0.1  2.5 ±0.1  
Nau (mmol/l) 143 ±1  142 ±1  143 ±1  143 ±1  
Kv (mmol/l) 5.9 ±0.1  5.3 ±0.5  5.7 ±0.2  5.7 ±0.6  
FEMALE                                                      Mean ± S.D. 
ASTa (IU/l) 135±24  145±39 150±40  136±48 
ALTb (IU/l) 26±4  26±6  26±3  26±7  
ALPc (IU/l) 587±197  498±88  513±115  504±131  
GGTd (IU/l) 0.2±0.4  0.8±0.4  0.2±0.4  0.2±0.4  
LDHe (IU/l) 1343±525  1540±893  1545±622  1326±834  
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BUNf (㎎/dl) 15.0±1.4  16.0±2.3  14.1±2.7  14.2±2.8  
CREg (㎎/dl) 0.40±0.05  0.42±0.05  0.45±0.06  0.41±0.04  
GLUh (㎎/dl) 101±10  113±7  107±23  100±11  
CHOi (㎎/dl) 77±10  88±10  72±14  91±24  
TPj (g/dl) 5.9±0.5  5.7±0.2  5.7±0.2  5.7±0.3  
CPKk (U/l) 1109±473  1011±527  1064±456  989±536  
ALBl (g/dl) 2.6±0.3  2.5±0.1  2.5±0.1  2.5±0.1  
T-BILm( (mg/dl) 0.03±0.01  0.04±0.01  0.03±0.02  0.03±0.01  
A/G ration 0.82±0.05  0.80±0.06  0.78±0.04  0.80±0.02  
TGo (㎎/dl) 28±11  30±13  30±13  48±29  
UAp (㎎/dl) 2.2±0.6  2.3±0.3  2.4±0.4  2.3±0.5  
Caq (㎎/dl) 10.6±0.1  10.5±0.3  10.3±0.5  10.7±0.6  
IPr (㎎/dl) 10.5±0.5  11.0±0.5  11.0±0.9  11.2±0.2  
Cls (mmol/l) 106±2  106±2  106±1  106±2  
Mgt (㎎/dl) 2.9±0.3  2.8±0.2  2.9±0.3  2.9±0.3  
Nau (mmol/l) 142±1  141±1  141±2  142±1  
Kv (mmol/l) 5.9±0.7  6.1±1.2  6.1±0.8  6.2±0.8  
Each group consisted of five animals of both sexes. Value are the mean±standard deviation. a: Aspartate 
aminotransferase, b: Alanine aminotransferase, c: alkaline phosphatase, d: Gamma(γ)-glutamyl transferase, e: 
Lactate dehydrogenase, f: Blood urea nitrogen, g: Creatinine, h: Glucose, i: Total cholesterol, j: Total protein, k: 
Creatine phosphokinase, l: Albumin, m: Total bilirubin, n: Albumin/Globulin ratio, o: Triglyceride, p: Uric acid, 
q: Calcium, r: Inorganic phosphorus, s: Chloride, t: Magnesium, u: Sodium, v: Potassium 
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0  500  1,000  2,000  
Male Mean ± S.D. 
Body weight 268.45±9.06  283.13±14.01  291.02±14.26  277.45±9.88  
Testis (Lt.) 1.4341±0.1257  1.4051±0.0429  1.3660±0.1956  1.2341±0.4618  
Testis (Rt.) 1.4026±0.1349  1.4322±0.0614  1.3537±0.1851  1.4678±0.1403  
Prostate 0.4041±0.0842  0.4043±0.1142  0.3869±0.0727  0.3696±0.0682  
Spleen 0.6005±0.1105  0.7994±0.2393  0.7258±0.0654  0.7457±0.1503  
Liver 8.4166±0.4019  9.3058±0.9886  9.4535±1.0318  8.5626±0.4509  
Adrenal gland (Lt.) 0.0281±0.0041  0.0316±0.0040  0.0296±0.0035  0.0239±0.0086  
Adrenal gland (Rt.) 0.0259±0.0031  0.0286±0.0029  0.0273 ±0.0031  0.0268±0.0030  
Kidney (Lt.) 1.0696±0.1033  1.2041±0.0547  1.1669±0.2054  1.1334±0.1108  
Kidney (Rt.) 1.1273±0.1389  1.2247±0.0895  1.1636±0.1388  1.1732±0.0647  
Heart 1.0062±0.0939  1.0637±0.0556  1.0934±0.0702  1.0766±0.0396  
Lung 1.2356±0.1005  1.4054±0.1464  1.3416±0.1532  1.4252±0.2591  
Brain 1.8860±0.0873  1.9088±0.0324  1.9718±0.0328  1.9123±0.1035  
Thymus 0.5885±0.1583  0.6018±0.1580  0.7551±0.0920  0.5430±0.0643  
Female Mean ± S.D. 
Body weight 189.17±11.56  187.29±14.35  186.44±13.82  188.34±13.01  
Ovary (Lt.) 0.0434±0.0056  0.0380±0.0126  0.0464±0.0107  0.0370±0.0044  
Ovary (Rt.) 0.0403±0.0055  0.0382±0.0074  0.0469±0.0068  0.0372±0.0107  
Uterus 0.4398±0.2482  0.3614±0.0636  0.4817±0.1364  0.5619±0.2637  
Spleen 0.4527±0.0615  0.4689±0.0752  0.4817±0.1200  0.4563±0.0519  
Liver 6.5668±0.5396  6.2212±0.7046  6.4795±0.5037  6.1319±0.7056  
Adrenal gland (Lt.) 0.0318±0.0053  0.0302±0.0047  0.0355±0.0037  0.0321±0.0042  
Adrenal gland (Rt.) 0.0312±0.0056  0.0279±0.0035  0.0335±0.0038  0.0296±0.0017  
Kidney (Lt.) 0.8609±0.1147  0.8170±0.1091  0.8894±0.1395  0.8126±0.1197  
Kidney (Rt.) 0.8760±0.1122  0.8238±0.1069  0.8738±0.1320  0.8318±0.1208  
Heart 0.7755±0.0756  0.7378±0.1023  0.7614±0.0392  0.7664±0.0644  
Lung 1.1800±0.1608  1.0658±0.1025  1.2599±0.1781  1.3749±0.4174  
Brain 1.8890±0.0822  1.8071±0.0900  1.8545±0.0720  1.8454±0.0624  





Nanotechnology is rapidly growing and will undoubtedly have both beneficial and 
toxicological effect and consequences on human beings and the environment (Arora et 
al., 2012). Nanotechnology promises to far exceed the impact of the Industrial 
Revolution and is projected to become a US$ 1 trillion market by 2015 (Drobne, 2007). 
The importance of nanotechnology to our lives is beyond debate. Yet, potential adverse 
effects need to be studied. Nanotoxicology was proposed as a new branch of 
toxicology to address the gaps in knowledge and to specifically address the adverse 
health effects likely to be caused by nanomaterials (Donaldson et al., 2004). In various 
fields, including those involving food, many nanomaterials and nanotechnology are 
already on the market. Currently, there are no special regulations for food-related 
nanotechnology. The Food and Drug Administration (FDA) regulates on a product-by-
product basis and points out many products made using currently regulated 
nanoparticles (FDA, 2004; Weiss et al., 2006).  
 Calcium is vitally important for maintaining health. Calcium deficiency leads to 
osteoporosis. However, the absorption efficiency of calcium is low. To overcome this 
limitation, the use of nano-sized calcium has been explored. Nanocalcium shares 
properties with microcalcium. But, there may be differences in ADME, including 
toxicity, as a consequence of the increased specific surface area of nanoparticles.  
 The possible toxicity of nanoparticles in food is an important issue, even in the 
absence of specific legislation mandating such studies. The physicochemical properties 
45 
 
of the nanomaterials including nanocalcium needs to be well characterized and the use 
of appropriate dose metrics is very important for toxicity testing. The characterization 
of nanofoods before and after in vitro and in vivo administration is also needed in 
screening studies. Huang et al. (2009) used TEM analyses to demonstrate that 
administering nanocalcium carbonate and nanocalcium citrate can enhance the serum 
calcium concentration and maintain the whole body bone mineral density in 
ovariectomized mice. Hu et al. (2010) estimated the safety of nanocalcium using an in 
vitro assay conducted with bone marrow mesenchymal stem cells. In this report, they 
provided physico-chemical information through TEM, SEM, XRD and FT-IR. Park et 
al. (2008) found that consumption of nanocalcium enriched milk resulted in increased 
urinary excretion of calcium and decreased excretion of deoxypyridinoline and 
hydroxyproline in ovary ectomized rats. Despite the prior knowledge concerning 
characterization, efficiency, and safety estimation of nanocalcium, more information 
on the physico-chemical properties and genotoxicity of nanocalcium is needed.  
Presently, we analyzed nanocalcium and microcalcium samples by EF-TEM, FE-
SEM, DLS and XRD method. EF-TEM revealed nanocalcium and microcalcium 
diameters ranging from 50 nm to 1μm (Figure 1A) and 1 μm to 10 μm (Figure 1B), 
respectively. Both samples agglomerated, which prevented accurate determination of 
their average size by EF-TEM (Figure 1). To better gauge their agglomerated shape, 
we used SEM (Figure 2). To determine hydrodynamic diameters, both samples were 
analyzed by DLS, which revealed various size fractions (Figure 4). However, despite 
the size different, the same crystalline property was evident by XRD (Figure 3). BET-
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determined specific surface area of nanocalcium was 12.90 ± 0.27 m2/g and that of 
microcalcium was 12-times smaller, at 1.12 ± 0.19 m2/g (Table 1). Previously, we 
reported that ROS formation in silver and zinc oxide nanoparticles and linked ROS 
formation with toxicity (Kim et al., 2007; Park et al., 2011). Presently, ESR did not 
reveal a ROS signal in either particle type (Table 1).  
 ICP-OES revealed that the release of 2–3 times more Ca2+ from nanocalcium than 
from microcalcium at pH 5 and pH 7 (Table 2). For nanomaterials like calcium, which 
can ionize and agglomerate, it may be important to provide information for specific 
surface area and degree of ionization to asset their toxicity and toxic mechanism.  
Genotoxicity was presently explored using a chromosomal aberration test, micro 
nucleus assay, and bacterial reverse mutation assay in accordance with KFDA 
notification and OECD Test Guidelines. Nanocalcium did not show any apparent 
genotoxicity in the recommended high concentration (Tables 3, 4, and 5).  
In vivo toxicity testing, also done in accordance with KFDA notification and OECD 
Test Guideline, involved four groups (10 rats per group, always comprising five 
females and five males) at each dose level. No severe toxicity was observed in the 
single-dose acute oral toxicity test and the repeated-dose 14-day oral toxicity test 
(Figure 6, Tables 6, 7, and 8).  
Nanocalcium did not pose genotoxicity and in in vivo toxicity problems in our 
experimental conditions. In the United States Toxic Substances Control Act (TSCA) 
inventory, calcium carbonate (CAS# 471-34-1) is classified in the group with the least 
toxicity (LD50 of calcium carbonate, 6450 mg/kg). Presently, nanocalcium exhibited 
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the same physicochemical properties and was also regarded as having low toxicity in 
vivo. 
Yet, we should be hasty in concluding that toxicity of nanocalcium is same or 
different as microcalcium. Nanocalcium has a large specific surface area and a greater 
potential for ionization (Tables 1 and 2). These properties of nanocalcium will lead to 
different results in long-term monitoring. The present BET and ICP-OES analyses 
highlight the need for long-term monitoring after administration, due to their 
differential of ionization derived from their different specific surface areas. Differential 
toxicity could exist in sub-chronic tests of nanocalcium; thus, it is not enough to 
provide size information based on TEM, SEM, and DLS in the case of agglomerated 
samples to explain their differential toxicity. The current findings indicate that BET 
and ICP-OES may provide more reasonable information about the differential between 
nano-sized calcium and microcalcium by calculating the surface area of agglomerated 
nano-materials.  
We hope that this report will contribute to the determination of the concentration of 
the high dose group in 13-week oral repeated dose toxicity test of nanocalcium, and 
helps indicate the utility of BET in measuring the specific surface area and of ICP-OES 
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국  논   
 
리  특 에  나노칼슘  안  평가 
(지도 : 조 명 행) 
 
조   
 
울  원 
과 , 독  공 
 
이 연구는 리  특  여 나노칼슘  잠재 인 독  평가  
해 행 었다. 국 식품 약품안 청 부  공  7개  샘  에 지 여
과 투과 자 미경 검사 (EF-TEM), X  회 분  (XRD)를 이용  분분 , 
그리고 에 지 분산  분 분 법  맹검법  시험  후에 나노칼슘과 마이크  
칼슘 2개  샘  다  시험  해 택 다. 나노칼슘과 마이크 칼슘  특
 EF-TEM, FE-TEM, XRD, 동  산란, 그리고 자스  공명법  평가
었다. 가지 시료 모  집이 이 찰 었고, 산소 역시 생 지 않았
다. N2 Brunauere Emmette Teller (BET) 법   나노칼슘과 마이크
칼슘  면  각각 12.90 ± 0.27 m2/g, 그리고 1.12 ± 0.19 m2/g 다. 
도결합 라즈마원자분 (Inductively coupled plasma optical emission 
spectrometry)분  pH 5  7에  칼슘이  출이 마이크 칼슘과 
여 나노칼슘에  2~3  가  보 다. 나노칼슘  안  평가  해 
독 시험과 Sprague-Dawley 를 이용  단회투여 독 시험 그리고 복 투여 
경구독 시험  행 다. BET  ICP-OES 분 결과는 나노칼슘  면 이 
 크고 이  가능 이  크다는 것  보여 다. 독 시험과 in vivo 독 시
험에  나노칼슘  독  보이지 않았다. 지만 나노칼슘  그것  이  
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면  차이 때 에 장 인 모니 링이 요 다.   
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